Multifunctional roles of urokinase plasminogen activator (uPA) in cancer stemness and chemoresistance of pancreatic cancer

被引:41
|
作者
Asuthkar, Swapna [1 ]
Stepanova, Victoria [4 ]
Lebedeva, Tatiana [4 ]
Holterman, AiXuan L. [2 ]
Estes, Norman [2 ]
Cines, Douglas B. [4 ]
Rao, Jasti S. [1 ]
Gondi, Christopher S. [3 ]
机构
[1] Univ Illinois, Coll Med Peoria, Dept Canc Biol & Pharmacol, Peoria, IL 61605 USA
[2] Univ Illinois, Coll Med Peoria, Dept Surg, Peoria, IL 61605 USA
[3] Univ Illinois, Coll Med Peoria, Dept Med, Peoria, IL 61605 USA
[4] Univ Penn, Dept Pathol & Lab Med, Perelman Sch Med, Philadelphia, PA 19104 USA
关键词
EPITHELIAL-MESENCHYMAL TRANSITION; TUMOR-STROMAL INTERACTIONS; GLIOMA-CELL INVASION; DOWN-REGULATION; RECEPTOR UPAR; SIDE POPULATION; ANTISENSE UPAR; HAIRPIN RNA; EXPRESSION; GROWTH;
D O I
10.1091/mbc.E12-04-0306
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Pancreatic ductal adenocarcinoma (PDAC) is almost always lethal. One of the underlying reasons for this lethality is believed to be the presence of cancer stem cells (CSC), which impart chemoresistance and promote recurrence, but the mechanisms responsible are unclear. Recently the poor prognosis of PDAC has been correlated with increased expression of urokinase plasminogen activator (uPA). In the present study we examine the role of uPA in the generation of PDAC CSC. We observe a subset of cells identifiable as a side population (SP) when sorted by flow cytometry of MIA PaCa-2 and PANC-1 pancreatic cancer cells that possess the properties of CSC. A large fraction of these SP cells are CD44 and CD24 positive, are gemcitabine resistant, possess sphere-forming ability, and exhibit increased tumorigenicity, known characteristics of cancer stemness. Increased tumorigenicity and gemcitabine resistance decrease after suppression of uPA. We observe that uPA interacts directly with transcription factors LIM homeobox-2 (Lhx2), homeobox transcription factor A5 (HOXA5), and Hey to possibly promote cancer stemness. uPA regulates Lhx2 expression by suppressing expression of miR-124 and p53 expression by repressing its promoter by inactivating HOXA5. These results demonstrate that regulation of gene transcription by uPA contributes to cancer stemness and clinical lethality.
引用
收藏
页码:2620 / 2632
页数:13
相关论文
共 50 条
  • [21] The prognostic relevance of urokinase-type plasminogen activator (uPA) in the blood of patients with metastatic breast cancer
    Malgorzata Banys-Paluchowski
    Isabell Witzel
    Bahriye Aktas
    Peter A. Fasching
    Andreas Hartkopf
    Wolfgang Janni
    Sabine Kasimir-Bauer
    Klaus Pantel
    Gerhard Schön
    Brigitte Rack
    Sabine Riethdorf
    Erich-Franz Solomayer
    Tanja Fehm
    Volkmar Müller
    Scientific Reports, 9
  • [22] Urokinase plasminogen activator (uPA) and soluble urokinase plasminogen activator receptor (suPAR) serum level in patients with malignant lymphomas
    Hus, I
    Cioch, M
    Jawniak, D
    Manko, J
    Dmoszynska, A
    Chrapko, M
    Hus, M
    BULLETIN OF THE VETERINARY INSTITUTE IN PULAWY, 2002, : 141 - 144
  • [23] INVOLVEMENT OF UROKINASE PLASMINOGEN-ACTIVATOR (UPA) IN KERATINOCYTE PROLIFERATION
    HIBINO, T
    TAKAHASHI, T
    LEUTHARDT, D
    GOETINCK, PF
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1994, 102 (04) : 641 - 641
  • [24] Targeting the Urokinase Plasminogen Activator Pathway in Combination With Chemotherapy Inhibits Pancreatic Cancer Progression
    Hosen, S. M. Z.
    Xu, Z.
    Perera, C.
    Mekapogu, A. R.
    Pang, T. C. Y.
    Goldstein, D.
    Pirola, R. C.
    Wilson, J. S.
    Buckley, B. J.
    Ranson, M.
    Apte, M. V.
    PANCREAS, 2021, 50 (07) : 1065 - 1065
  • [25] Prognostic relevance of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in gastric cancer
    Ito, H
    Yonemura, Y
    Fujita, H
    Tsuchihara, K
    Kawamura, T
    Nojima, N
    Fujimura, T
    Nose, H
    Endo, Y
    Sasaki, T
    VIRCHOWS ARCHIV, 1996, 427 (05) : 487 - 496
  • [26] Exosomes and their roles in the chemoresistance of pancreatic cancer
    Pan, Yubin
    Tang, Honglin
    Li, Qijun
    Chen, Guangpeng
    Li, Da
    CANCER MEDICINE, 2022, 11 (24): : 4979 - 4988
  • [27] Urokinase plasminogen activator (uPA) and plasminogen activator inhibitor type-1 (PAI-1) in breast cancer - correlation with traditional prognostic factors
    Lampelj, Maja
    Arko, Darja
    Cas-Sikosek, Nina
    Kavalar, Rajko
    Ravnik, Maja
    Jezersek-Novakovic, Barbara
    Dobnik, Sarah
    Dovnik, Nina Fokter
    Takac, Iztok
    RADIOLOGY AND ONCOLOGY, 2015, 49 (04) : 357 - 364
  • [28] The role of the urokinase-type plasminogen activator (uPA) and its inhibitor (PAI-1) in breast cancer
    Takac, Iztok
    Cufer, Tanja
    Gorisek, Borut
    Cas-Sikosek, Nina
    Bali, Robert
    Bosilj, Damijana
    Borstnar, Simona
    Lampelj, Maja
    Ravnik, Maja
    Kavalar, Rajko
    Fokter, Nina
    Arko, Darja
    ZDRAVNISKI VESTNIK-SLOVENIAN MEDICAL JOURNAL, 2011, 80 (05): : 405 - 412
  • [29] Å6, a urokinase plasminogen activator (uPA)-derived peptide in patients with advanced gynecologic cancer:: A phase I trial
    Berkenblit, A
    Matulonis, UA
    Kroener, JF
    Dezube, BJ
    Lam, GN
    Cuasay, LC
    Brünner, N
    Jones, TR
    Silverman, MH
    Gold, MA
    GYNECOLOGIC ONCOLOGY, 2005, 99 (01) : 50 - 57
  • [30] Urokinase-like plasminogen activator receptor (UPA-R) expression on disseminated breast cancer cells
    Tögel, F
    Datta, C
    Badbaran, A
    Kröger, N
    Renges, H
    Gieseking, F
    Jänicke, F
    Zander, AR
    Krüger, WH
    BONE MARROW TRANSPLANTATION, 2001, 27 : S239 - S239